US biotech Vertex Pharmaceuticals (Nasdaq: VRTX) has reported full-year product revenues of $7.57 billion for 2021, a 22% increase compared to 2020, while adjusted earnings were 26% higher at $13.02.
Quarterly sales came in at $2.07 billion, beating stock analysts' $2 billion prediction and 27% ahead of the same period in 2020.
"Our pipeline beyond CF accelerated and delivered important clinical data in new disease areas"Adjusted earnings for the quarter also soared 34% to $3.37 per share, ahead of the $3.29 predicted by analysts.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze